Bursitis Treatment Market by Type, Drug Type, End-User

List of Tables

[195 Pages Report] The Bursitis Treatment Market size was estimated at USD 7.81 billion in 2023 and expected to reach USD 8.14 billion in 2024, at a CAGR 4.58% to reach USD 10.69 billion by 2030.

Bursitis is a medical condition characterized by inflammation or irritation of a bursa, which is a small fluid-filled sac located near the joints. Bursae function as cushions, reducing friction between the bones and other moving parts, including muscles, tendons, and skin. When these sacs become inflamed, the affected area can experience pain, swelling, and restricted movement. Bursitis treatment refers to the various methods used to loosen the inflammation and pain caused by bursitis, a condition where the bursae become inflamed. Increases in the incidence of musculoskeletal disorders, including arthritis, gout, and diabetes, escalate the risk of developing bursitis. Enhanced understanding of the condition and greater investment in health infrastructure contribute to market expansion. However, bursitis symptoms often mimic those of other joint disorders, potentially leading to misdiagnosis and ineffective treatments. Furthermore, developing regions are observing increased healthcare infrastructure, presenting new markets for bursitis treatments. Improved diagnostic tools and treatment options enhance market growth opportunities by providing more effective and faster results.

KEY MARKET STATISTICS
Base Year [2023]	USD 7.81 billion
Estimated Year [2024]	USD 8.14 billion
Forecast Year [2030]	USD 10.69 billion
CAGR (%)	4.58%

Regional Insights

The United States is a significant market for bursitis treatment due to a high prevalence of musculoskeletal conditions. Advanced healthcare infrastructure, widespread awareness about the condition, and active participation in sports leading to sports injuries contribute to a higher demand for effective treatments. The market is characterized by the presence of leading pharmaceutical companies investing heavily in research and development. Ongoing innovation in the United States focuses on novel anti-inflammatory drugs and minimally invasive surgical procedures that promise faster recovery and fewer side effects. EU countries show a strong demand for bursitis treatments driven by an aging population and a high rate of sports activities. Regulations and healthcare policies across the EU emphasize safe and effective treatments, steering research towards safer pharmacological interventions and physiotherapy techniques. EU-funded projects often focus on improving diagnosis and treatments for musculoskeletal disorders, including bursitis, under broader health initiatives. The treatment market in the Middle East is growing and is influenced by improving healthcare facilities and increasing disposable incomes. APAC, with a large population and increasing elderly demographic, makes it a noteworthy market for bursitis treatments. The government's push towards healthcare reform and enhancing the quality of life for the aging population has fueled research and development.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the Bursitis Treatment Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers
- Rising incidence of musculoskeletal disorders globally
- Increased awareness coupled with rising investment in health infrastructure

Market Restraints
- Strict government regulations regarding drug approval

Market Opportunities
- Advancements in diagnostic tools and treatment options in bursitis
- Ongoing innovation in drug development formulations

Market Challenges
- Complexities associated with diagnostic and lack of reimbursement policies

Market Segmentation Analysis
- Type: Chronic bursitis prefer treatments to address pain management and prevention of further joint damage
- End-User: Hospitals and clinics offer better accessibility for the immediate care required for acute bursitis

Market Disruption Analysis
Porter's Five Forces Analysis
Value Chain & Critical Path Analysis
Pricing Analysis
Technology Analysis
Patent Analysis
Trade Analysis
Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Bursitis Treatment Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Bursitis Treatment Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Endo Pharmaceuticals Introduces Generic Version of Duexis: Ibuprofen-Famotidine Tablets

Endo Pharmaceuticals has launched a new generic medication containing ibuprofen and famotidine, which serves as a counterpart to the branded drug Duexis. This new generic product is specifically formulated to simultaneously alleviate pain and reduce the risk of stomach ulcers, addressing the dual needs of patients who require nonsteroidal anti-inflammatory drugs (NSAIDs) for conditions such as bursitis while safeguarding their gastrointestinal health. [Published On: 2024-03-26]

FDA Greenlights Innovative Corticosteroid for Duchenne Muscular Dystrophy Management

The U.S. Food and Drug Administration (FDA) has approved a new corticosteroid treatment for patients with Duchenne Muscular Dystrophy (DMD). This novel therapeutic option is designed to provide the benefits of traditional corticosteroid therapy but with reduced adverse effects. This approval marks a significant advancement in managing DMD, offering a more tolerable and potentially effective treatment alternative. [Published On: 2023-10-27]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Bursitis Treatment Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Bursitis Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Arinna Lifesciences Ltd., AstraZeneca PLC, Bioanalytical Systems, Inc., Bristol-Myers Squibb Company, Crescent Formulations Pvt.Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Merck & Co., Inc., NIDEK CO., LTD., Novartis AG, Perrigo Company PLC, Pfizer Inc., Sanofi S.A., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., and Topcon Corporation.

Market Segmentation & Coverage

This research report categorizes the Bursitis Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
- Acute Bursitis
- Chronic Bursitis

Drug Type
- Medication
  - Corticosteroids
  - Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
  - Physical Therapy

Physical Therapy

End-User
- Hospitals & Clinics
- Rehabilitation Centers

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

Product Code: MRR-5D693B46C73C

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising incidence of musculoskeletal disorders globally
  - 5.1.1.2. Increased awareness coupled with rising investment in health infrastructure
- 5.1.2. Restraints
  - 5.1.2.1. Strict government regulations regarding drug approval
- 5.1.3. Opportunities
  - 5.1.3.1. Advancements in diagnostic tools and treatment options in bursitis
  - 5.1.3.2. Ongoing innovation in drug development formulations
- 5.1.4. Challenges
  - 5.1.4.1. Complexities associated with diagnostic and lack of reimbursement policies
5.2. Market Segmentation Analysis
- 5.2.1. Type: Chronic bursitis prefer treatments to address pain management and prevention of further joint damage
- 5.2.2. End-User: Hospitals and clinics offer better accessibility for the immediate care required for acute bursitis
5.3. Market Disruption Analysis
5.4. Porter's Five Forces Analysis
- 5.4.1. Threat of New Entrants
- 5.4.2. Threat of Substitutes
- 5.4.3. Bargaining Power of Customers
- 5.4.4. Bargaining Power of Suppliers
- 5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis

6. Bursitis Treatment Market, by Type

6.1. Introduction
6.2. Acute Bursitis
6.3. Chronic Bursitis

7. Bursitis Treatment Market, by Drug Type

7.1. Introduction
7.2. Medication
7.3. Physical Therapy

8. Bursitis Treatment Market, by End-User

8.1. Introduction
8.2. Hospitals & Clinics
8.3. Rehabilitation Centers

9. Americas Bursitis Treatment Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Bursitis Treatment Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Bursitis Treatment Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
- 12.3.1. Endo Pharmaceuticals Introduces Generic Version of Duexis: Ibuprofen-Famotidine Tablets
- 12.3.2. FDA Greenlights Innovative Corticosteroid for Duchenne Muscular Dystrophy Management
12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

13.1. Key Company Profiles
13.2. Key Product Portfolio